<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Robinhood &amp; Applovin, SpaceX &amp; EchoStar, Summit Therapeutics — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Robinhood &amp; Applovin, SpaceX &amp; EchoStar, Summit Therapeutics</h2>
    <div class="badge">2025-09-08T13:33:35+00:00</div>
    <ul>
      <li>Now, next up, Echostar striking a $17 billion deal with Elon Musk&#x27;s SpaceX.</li>
<li>The space exploration company agreed to acquire wireless spectrum from Echostar for about $17 billion in cash and stock.</li>
<li>Well, let&#x27;s start with the S&amp;P 500&#x27;s soon to be members.</li>
<li>We&#x27;re watching Echostar, Summit therapeutics and new additions to the S&amp;P 500.</li>
<li>The drug has drawn scrutiny as a potential rival to the world&#x27;s top-selling cancer therapy and became a symbol of China&#x27;s biotech ambitions after Summit licensed it from Aso in a deal that could be worth $5 billion.</li>
<li>Now, time for some of today&#x27;s trending tickers.</li>
<li>Ramzan Karmali examines some of Monday&#x27;s trending tickers: Robinhood (HOOD), Applovin (APP), and EMCOR&#x27;s (EME) joining the S&amp;P 500 (^GSPC), the SpaceX (SPAX.PVT) and EchoStar (SATS) deal, and Summit Therapeutics&#x27; (SMMT)</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Robinhood &amp;amp; Applovin, SpaceX &amp;amp; EchoStar, Summit Therapeutics\n• Now, next up, Echostar striking a $17 billion deal with Elon Musk&#x27;s SpaceX.\n• The space exploration company agreed to acquire wireless spectrum from Echostar for about $17 billion in cash and stock.\n• Well, let&#x27;s start with the S&amp;P 500&#x27;s soon to be members.\n• We&#x27;re watching Echostar, Summit therapeutics and new additions to the S&amp;P 500.\n• The drug has drawn scrutiny as a potential rival to the world&#x27;s top-selling cancer therapy and became a symbol of China&#x27;s biotech ambitions after Summit licensed it from Aso in a deal that could be worth $5 billion.\n• Now, time for some of today&#x27;s trending tickers.\n• Ramzan Karmali examines some of Monday&#x27;s trending tickers: Robinhood (HOOD), Applovin (APP), and EMCOR&#x27;s (EME) joining the S&amp;P 500 (^GSPC), the SpaceX (SPAX.PVT) and EchoStar (SATS) deal, and Summit Therapeutics&#x27; (SMMT)" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/video/robinhood-applovin-spacex-echostar-summit-133335577.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>